Daniel Hetu
Corporate Officer/Principal at LAVA MEDTECH ACQUISITION CORP.
Profile
Daniel Hetu is currently a Managing Director at Lumira Capital Investment Management, Inc. He also holds director positions at Gladius Pharmaceuticals, Inc., Gladius Pharmaceuticals Corp., Xylocor Therapeutics, Inc., Kisoji Biotechnology, Inc., Transposon Therapeutics, Inc., Specific Biologics, Inc., Congruence Therapeutics, Inc., and is an Executive Vice President at LAVA Medtech Acquisition Corp.
In the past, Dr. Hetu has worked as a Director at Cardiac Dimensions, Inc., Resonant Medical, Inc., U-Systems, Inc., Réseau Capital, IMV, Inc., Thrasos Therapeutics, Inc., and Opsens Medical.
He was also a Director and Vice President at OsteoqQC, Inc. from 2014 to 2022.
Additionally, he held positions as Vice President of Corporate Development at Biochem Pharma, Inc. and Vice President of Business Development at Shire Pharmaceuticals, Inc.Dr. Hetu holds a doctorate degree from the University of Sherbrooke and an MBA from École des Hautes Études Commerciales de Paris.
Daniel Hetu active positions
| Companies | Position | Start |
|---|---|---|
| LAVA MEDTECH ACQUISITION CORP. | Corporate Officer/Principal | - |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Private Equity Investor | 31/12/2004 |
Kisoji Biotechnology, Inc.
 Kisoji Biotechnology, Inc. BiotechnologyHealth Technology Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada. | Director/Board Member | - |
Transposon Therapeutics, Inc.
 Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | Director/Board Member | - |
Congruence Therapeutics, Inc.
 Congruence Therapeutics, Inc. BiotechnologyHealth Technology Congruence Therapeutics, Inc. operates as a Canadian biotechnology company. The company is based in Westmount, Canada. Congruence Therapeutics was founded in 2021 by Clarissa Desjardins, who has been the CEO since 2021. | Director/Board Member | - |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director/Board Member | - |
Gladius Pharmaceuticals Corp.
 Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Director/Board Member | - |
Gladius Pharmaceuticals, Inc.
 Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Director/Board Member | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Board Member | - |
Former positions of Daniel Hetu
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Daniel Hetu
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
| University of Sherbrooke | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| IMV INC. | Health Technology |
| Private companies | 18 |
|---|---|
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
Réseau Capital
 Réseau Capital Miscellaneous Commercial ServicesCommercial Services Réseau Capital operates as a venture capital and private equity association. It promotes private equity industry in Quebec through training, information and promotion, networking, and representation. The company was founded by Jean-Pierre Chartrand in 1989 and is headquartered in Montréal, Canada. | Commercial Services |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Biochem Pharma, Inc.
 Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Health Technology |
Thrasos Therapeutics, Inc.
 Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Cardiac Dimensions, Inc.
 Cardiac Dimensions, Inc. Medical SpecialtiesHealth Technology Cardiac Dimensions, Inc. develops novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. It offers the CARILLON Mitral Contour System, a proprietary and implantable device designed to be positioned in the coronary sinus vein using cardiac catheterization techniques. The firm also offers patient enrollment, clinical testing, and medical consulting services. The company was founded by James W. Fitzsimmons and Scott Jordan Wolf in 2001 and is headquartered in Kirkland, WA. | Health Technology |
Gladius Pharmaceuticals, Inc.
Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Health Technology |
OsteoqQC, Inc.
 OsteoqQC, Inc. BiotechnologyHealth Technology OsteoqQC, Inc. develops drugs for the treatment of bone-related diseases. The company was founded by Debra Ellies and is headquartered in Montreal, Canada. | Health Technology |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Health Technology |
Kisoji Biotechnology, Inc.
Kisoji Biotechnology, Inc. BiotechnologyHealth Technology Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
LAVA Medtech Acquisition Corp.
 LAVA Medtech Acquisition Corp. Financial ConglomeratesFinance LAVA Medtech Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on March 31, 2021 and is headquartered in Waltham, MA. | Finance |
Opsens Medical
 Opsens Medical Electrical ProductsProducer Manufacturing Part of Opsens, Inc., Opsens Medical is a Canadian company focused on improving cardiovascular disease diagnosis and treatment. The company is based in Quebec, Canada. Established in 2003, the company believes in the power of innovative technologies to find solutions to challenges and unmet needs in various markets. Opsens Medical capitalizes on its expertise in coronary physiology to extend its activities to the fast-growing sector of structural cardiology. | Producer Manufacturing |
U-Systems, Inc.
 U-Systems, Inc. Medical SpecialtiesHealth Technology U-Systems, Inc. designs, develops, manufactures and markets ultrasound systems. The company was founded in 1997 and is headquartered in Schenectady, NY. | Health Technology |
Resonant Medical, Inc.
 Resonant Medical, Inc. Medical SpecialtiesHealth Technology Resonant Medical Inc. develops, manufactures and distributes 3D ultrasound image-guided adaptive radiotherapy products. The company was founded by Fred Francis, Tony Falco and Luc Sirois and is headquartered in Montréal, CA. | Health Technology |
Congruence Therapeutics, Inc.
Congruence Therapeutics, Inc. BiotechnologyHealth Technology Congruence Therapeutics, Inc. operates as a Canadian biotechnology company. The company is based in Westmount, Canada. Congruence Therapeutics was founded in 2021 by Clarissa Desjardins, who has been the CEO since 2021. | Health Technology |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | Health Technology |
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Stock Market
- Insiders
- Daniel Hetu
